Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY01008 vs bevacizumab plus paclitaxel/carboplatin in metastatic or recurrent non‑squamous NSCLC
CTR20171412Phase 3Completed
- Sponsor
- Boan Biotech
- Start
- Jan 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of bevacizumab MB02 in Non-small cell lung cancer (NS-NSCLC), sponsored by Boan Biotech. Started Jan 2018; status: completed.
02
Drugs
bevacizumab MB02
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on CTR20171412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20171412.